AeroVironment (AVAV) Raymond James TMT & Consumer Conference presentation summary

Strategic initiatives and acquisition

• Announced acquisition of BlueHalo in an all-stock transaction, creating a combined entity valued at ~$4.1B with AVAV shareholders owning 60.5% and BlueHalo shareholders 39.5%.

• BlueHalo brings advanced capabilities in space technologies, counter-UAS, electronic warfare, and cyber, with $900M+ in 2024E revenue and a $500M+ funded backlog.

• The acquisition is expected to be accretive to revenue, adjusted EBITDA, and non-GAAP EPS in the first full fiscal year post-close, with $20M in anticipated net cost synergies.

• BlueHalo will have two board seats, and its CEO will serve as a strategic advisor; closing is expected in 1H 2025, subject to regulatory and shareholder approvals.

• The combined company aims to become a leading defense technology prime, expanding its portfolio in high-growth, mission-critical segments.

Business segments and product portfolio

• Operates in three segments: Loitering Munition Systems (LMS), Uncrewed Systems (UxS), and MacCready Works (MW) for advanced R&D.

• LMS generated $193M in FY24 revenue, with key products like Switchblade and Blackwing, and growth opportunities in U.S. DoD initiatives and international expansion.

• UxS segment delivered $448M in FY24 revenue, offering UAVs, UGVs, and ground control solutions, with growth in Army and Navy programs and global markets.

• MacCready Works focuses on next-gen technologies, including HAPS, Mars Helicopter, and AI-powered solutions, with $76M in FY24 revenue.

• Product mix includes lethal drones, ground robots, logistic UAVs, space helicopters, and advanced software for autonomy and AI.

Financial performance and outlook

• Reported $761M in revenue, $313M adjusted gross profit, $114M adjusted EBITDA, and $2.42 non-GAAP EPS for the last twelve months through Q2 FY25.

• FY24 revenue grew 33% to $717M, with FY25 guidance of $790M–$820M (12% growth at midpoint), adjusted EBITDA of $143M–$153M, and non-GAAP EPS of $3.18–$3.49.

• R&D investment was $114M, and funded backlog stood at $467M as of Q2 FY25.

• Order visibility covers 95% of the FY25 revenue guidance range as of December 2024.

• Adjusted gross margins expected at 40–41% for FY25, with R&D expenses at 12–13% of revenue.